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Despite being a canonical presenting feature of mitochondrial disease, the genetic basis of progressive external ophthalmoplegia
remains unknown in a large proportion of patients. Here we show that mutations in SPG7 are a novel cause of progressive
external ophthalmoplegia associated with multiple mitochondrial DNA deletions. After excluding known causes, whole exome
sequencing, targeted Sanger sequencing and multiplex ligation-dependent probe amplification analysis were used to study 68
adult patients with progressive external ophthalmoplegia either with or without multiple mitochondrial DNA deletions in skel-
etal muscle. Nine patients (eight probands) were found to carry compound heterozygous SPG7 mutations, including three novel
mutations: two missense mutations c.2221G4A; p.(Glu741Lys), c.2224G4A; p.(Asp742Asn), a truncating mutation c.861dupT;
p.Asn288*, and seven previously reported mutations. We identified a further six patients with single heterozygous mutations in
SPG7, including two further novel mutations: c.184-3C4T (predicted to remove a splice site before exon 2) and c.1067C4T;
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p.(Thr356Met). The clinical phenotype typically developed in mid-adult life with either progressive external ophthalmoplegia/
ptosis and spastic ataxia, or a progressive ataxic disorder. Dysphagia and proximal myopathy were common, but urinary
symptoms were rare, despite the spasticity. Functional studies included transcript analysis, proteomics, mitochondrial network
analysis, single fibre mitochondrial DNA analysis and deep re-sequencing of mitochondrial DNA. SPG7 mutations caused
increased mitochondrial biogenesis in patient muscle, and mitochondrial fusion in patient fibroblasts associated with the
clonal expansion of mitochondrial DNA mutations. In conclusion, the SPG7 gene should be screened in patients in whom a
disorder of mitochondrial DNA maintenance is suspected when spastic ataxia is prominent. The complex neurological phenotype
is likely a result of the clonal expansion of secondary mitochondrial DNA mutations modulating the phenotype, driven by
compensatory mitochondrial biogenesis.
Keywords: chronic progressive external ophthalmoplegia; hereditary spastic paraplegia; paraplegin; mtDNA maintenance; SPG7
Abbreviations: COX = cytochrome c oxidase; PEO = progressive external ophthalmoplegia; SDH = succinate dehydrogenase
Introduction
Progressive external ophthalmoplegia (PEO) is a classical present-
ing feature of mitochondrial disease, but the primary genetic basis
has yet to be defined in a substantial proportion of patients. PEO
and ptosis often occur in isolation, sometimes causing transient
diplopia and significant field defects when severe, but in some
patients PEO is part of a complex disorder involving both neuro-
logical and non-neurological features (Laforeˆt et al., 1995). A skel-
etal muscle biopsy remains a central clinical investigation, with a
mosaic pattern of cytochrome c oxidase (COX)-deficient fibres and
ragged-red fibres (indicative of mitochondrial sub-sarcolemmal ac-
cumulation) being key diagnostic features in most, but not all
cases (Taylor et al., 2004).
In many patients with PEO, the underlying molecular defect is
either a point mutation or a single, large-scale rearrangement of
mitochondrial DNA (Moraes et al., 1989). However, a large pro-
portion of patients harbour multiple mitochondrial DNA deletions
in skeletal muscle which accumulate throughout life and cause the
disorder (Zeviani et al., 1989; Moslemi et al., 1996). Several
nuclear-encoded mitochondrial genes have been shown to cause
these secondary defects of mitochondrial DNA (Copeland, 2008),
but the underlying nuclear gene defect is not known in 50% of
cases. Defining the molecular aetiology of this group will have
direct implications for clinical management and genetic counsel-
ling, and also lead to novel mechanistic insights.
Here we show that mutations in the spastic paraplegia 7 gene
(SPG7), which codes for the protein paraplegin (Casari et al., 1998),
are an important cause of sporadic PEO with multiple mitochondrial
DNA deletions presenting in mid-adult life. We demonstrate
increased mitochondrial mass and hyperfused mitochondria in af-
fected individuals, and accelerated clonal expansion of mitochondrial
DNA mutations contributing to a complex neurological phenotype.
Materials and methods
Subjects
Whole exome sequencing was performed on eight subjects with PEO
and no relevant family history who had 42% COX-deficient fibres,
multiple deletions of mitochondrial DNA in skeletal muscle, and no
mutation in POLG1, POLG2, SLC25A4, C10orf2, RRM2B, TK2,
OPA1 and exons 5 and 13 of DNA2 (Ronchi et al., 2013).
Following our initial findings, SPG7 was sequenced in a further 60
patients with unexplained PEO and/or multiple mitochondrial DNA
deletions. Clinical details of patients with mutations are listed in
Table 1. This study was approved and performed under the ethical
guidelines issued by each of our institutions and complied with the
Declaration of Helsinki.
Exome sequencing
Whole blood genomic DNA was fragmented to 150–200 bp by
Adaptive Focused Acoustics (Covaris), end-paired, adenylated and
ligated to adapters. Exonic sequences were enriched using Agilent
SureSelect Target Enrichment (Agilent SureSelect Human All Exon
50 Mb kit). The captured fragments were purified and sequenced on
a GAIIx platform using 75 bp paired-end reads. Bioinformatic analysis
was performed using an in-house algorithm based on published tools.
Sequence was aligned to the human reference genome (UCSC hg19),
using NovoAlign (www.novocraft.com). The aligned sequence files
were reformatted using SAMtools and duplicate sequence reads
were removed using Picard. Single base variants were identified
using Varscan (v2.2) and indels were identified using Dindel (v1.01).
The raw lists of variants were filtered to include variants within the
Sequence Capture target regions (500 bp). On target variants were
annotated using wAnnovar and common variants with a minor allele
frequency4 0.02 that were present in the 1000 Genomes (February
2012 data release), the NHLBI-5400 Exome Sequencing Project and
191 unrelated in-house exomes were excluded. Rare, protein altering,
homozygous and compound heterozygous variants that fitted the
recessive disease model were identified.
Sanger sequencing and multiplex
ligation-dependent probe
amplification analysis
Sanger sequencing of SPG7 was performed in the entire cohort of
68 patients using custom-designed primers (http://frodo.wi.mit.edu),
PCR amplification with Immolase (Bioline), and Sanger sequencing
with BigDye Terminator v3.1 (Life Technologies) according to the
manufacturer’s protocol on a 3130XL Genetic Analyzer (Life
Technologies), addressing regions of poor exome coverage in the
eight original subjects. Exon deletions of SPG7 were assessed by
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multiplex ligation-dependent probe amplification (MRC-Holland kit
P089-A1) in patients with single heterozygous missense mutations.
Because of the close relationship of paraplegin with AFG3L2, we
also sequenced the mutational hotspots of AFG3L2 (exons 10, 15,
and 16; Cagnoli et al., 2010) in patients with single heterozygous
SPG7 mutations.
Muscle histochemistry and
mitochondrial DNA analysis
Cryostat sections (10 mm) were cut from transversely orientated muscle
blocks and subjected to COX, succinate dehydrogenase (SDH), and
sequential COX-SDH histochemical reactions (Taylor and Turnbull,
1997). Total genomic DNA was extracted from muscle by standard
procedures. Large-scale mitochondrial DNA rearrangements were
screened by long-range PCR using a pair of primers (L6249: nucleo-
tides 6249–6265; and H16215: nucleotides 16 225–16 196) to amplify
a 10 kb product in wild-type mitochondrial DNA (GenBank Accession
number NC_012920.1). The level of deleted mitochondrial DNA in
individual COX-deficient and COX-positive reacting muscle fibres iso-
lated by laser microcapture was determined by quantitative real-time
PCR using the ABI PRISM Step One real-time PCR System (Life
Technologies) as previously described (He et al., 2002). Furthermore,
the assessment of mitochondrial DNA copy number in patient muscle
was investigated by real-time PCR (Blakely et al., 2008).
Transcript expression using reverse
transcription-quantitative polymerase
chain reaction
Primary fibroblast cell lines were established from skin biopsies of four
patients with SPG7 mutations (Patients 1–4). Cultures were grown
using minimum essential medium (Life Technologies), with 10%
foetal calf serum, 2 mM L-glutamine, 50mg/ml streptomycin, 50 U/ml
penicillin, 110 mg/l Na-pyruvate and 50 mg/l uridine, trypsinized and
pelleted for RNA extraction. Cells were also grown with medium sup-
plemented with 100mg/ml of emetine [an inhibitor of nonsense
mediated messenger RNA decay; (Noensie et al., 2001)] for 10 h.
Cells were pelleted and RNA extracted using RNeasy Mini Kit
(Qiagen). For muscle RNA extraction, 30 mg of tissue (Patients 1–4,
and three control subjects) was homogenized over ice using a Potter-
type tissue homogenizer in RLT buffer (from RNeasy Mini Kit,
Qiagen) with 0.01% 2-mercaptoethanol. Homogenates were spun at
6000g for 5 min and supernatant used for RNA extraction as per the
protocol for RNeasy Mini Kit (Qiagen). Quality of extracted RNA was
analysed using the Agilent RNA 6000 Pico Kit with an Agilent
Bioanalyser 2100 (Agilent), as per the manufacturer’s instructions.
Extracted RNA used in this study had a RNA integrity number ranging
from 7.4–9.3.
Complementary DNA was generated using SuperScript III reverse
transcriptase kit and oligo dT primers (Life Technologies), as per manu-
facturer’s instructions. Transcript-specific primers for SPG7, AFG3L2,
OPA1, POLG, SDHA, and GAPDH (sequences available on request)
were used with SYBR Green (Life Technologies) on an IQ5 Bio-Rad
thermal cycler (Bio-Rad). Expression data were normalized to GAPDH.
Statistical analysis was performed in Microsoft Excel using F-test: two-
sample test for variances, followed by t-test: two sample assuming
equal or unequal variances. Statistical significance was considered
when P two-tail5 0.05. Sanger sequencing (see methods above) of
complementary DNA was also performed with transcript-specific
primers (sequences available upon request) to confirm the bi-allelic
nature of the compound heterozygous variants.
Western blot analysis
Muscle tissue from Patients 1, 2, 4, 5 and 7 and three control subjects
(30 mg) was homogenized over ice using a Potter-type tissue hom-
ogenizer in buffer containing 250 mM sucrose, 50 mM Tris-HCl pH
7.4, 5 mM MgCl2 (all Sigma) and protease inhibitor cocktail tablets
EDTA-free (Roche). Subsequently, TritonTM X-100 (Sigma) was
added to the final concentration of 1% and samples were sonicated
for 30 min on ice in a water bath sonicator. Total protein concentration
was measured by means of Bradford assay. Samples (20mg protein)
were separated through 4–15% Mini-PROTEAN TGXTM precast gels
(Bio-Rad) and transferred to polyvinylidene fluoride membranes using
Trans-Blot TurboTM transfer system (Bio-Rad). Membranes were
probed with antibodies specific to SPG7 (sc-135026, Santa Cruz
Biotechnology), AFG3L2 (14631-1-AP, Proteintech), OPA1 (MS995,
Mitosciences), SDHA (70kDa Complex II subunit) (MS204,
Mitosciences), porin (MSA03, Mitosciences), HSP60 (GTX110089,
GeneTex) and GAPDH (sc-25778HRP, Santa Cruz Biotechnology), fol-
lowed by species-appropriate horseradish peroxidase-conjugated sec-
ondary antibodies (Dako), using standard protocols. Protein signal was
detected with Pierce ECL2 Western Blotting substrate (Thermo
Scientific) and Biospectrum 500 Imaging System (UVP) as per manu-
facturer’s instructions. Densitometric analysis was performed using
ImageJ software (National Institute of Health). GAPDH was used to
normalize the results and the ratios protein of interest/GAPDH were
calculated. Data represent the mean of three independent replicates.
Statistical analysis was performed in Microsoft Excel using F-test: two-
sample test for variances, followed by t-test: two sample assuming
equal or unequal variances. Statistical significance was considered
when P two-tail5 0.05.
Mitochondrial network analysis
Cells from four SPG7 primary fibroblast cell lines (Patients 1–4) and
three control cell lines were cultured on glass bottom dishes (Willco,
HBSt-3522), and mitochondria were stained using MitoTracker Red
CMXRos at 0.75 nM. Live cell imaging was performed using Nikon
A1R inverted confocal microscope equipped with a 60 objective
(numerical aperture = 1.40), in culture medium without phenol red
and supplemented with 25 mM HEPES. Acquisitions were performed
at 3% laser power, at the frame size of 512  512 with perfect voxel
settings (x, y, z, 0.12mm). Sixty-nine z-planes across 8 mm were cap-
tured to allow for a 3D reconstruction of mitochondrial networks from
individual cells. Deconvolution and mitochondrial network analysis was
performed using Huygens Essentials software (SVI). Fifty cells were
imaged per individual cell line.
Deep resequencing of
mitochondrial DNA
PCR amplification of the mitochondrial DNA control region (MT-HVS2)
in muscle DNA from six patients (Patients 1, 2, 4, 5, 6 and 7) was per-
formed with tagged primers and ultra deep sequencing achieved using a
Roche 454 GS Titanium FLX platform as previously described (Payne
et al., 2011). An analysis pipeline of Pyrobayes, Mosiak, and a custom
R library was used to call and align the sequences to the mitochondrial
DNA reference along with a control cloned mitochondrial DNA sequence.
For quality control purposes, only sites covered by more than 10 000
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reads in each direction were considered for analysis. Data were compared
to muscle mitochondrial DNA from 22 in-house controls: seven healthy
individuals undergoing orthopaedic surgery (with two being over 65
years of age), eight with recessive POLG mutations known to cause a
high mutation burden, six with dominant OPA1 mutations known to
cause a defect of mitochondrial fusion-fission and control cloned mito-
chondrial DNA. Data were analysed as described previously (Payne et al.,
2013), with a 0.2% heteroplasmy detection threshold, based on the
sequencing of a cloned mitochondrial DNA template.
Results
Molecular genetics
Eight patients with PEO, multiple mitochondrial DNA deletions and
no known genetic defect were subjected to whole exome sequen-
cing. After excluding common variants found in the NHLBI-5400
Exome Sequencing project, 1000 Genomes and 191 in-house dis-
ease control subjects, we identified one patient with compound
heterozygous SPG7 mutations, one of which had not been previ-
ously reported (Patient 1) and another patient with a single het-
erozygous mutation within the SPG7 gene (Patient 12) (Table 1).
This led us to sequence SPG7 in the remaining larger cohort. Nine
patients from eight families were found to carry compound het-
erozygous SPG7 mutations, comprising three novel mutations: a
stop-gain mutation, c.861dupT p.Asn288* (Patient 1); and two
missense mutations c.2221G4A p.(Glu741Lys) and c.2224G4A
p.(Asp742Asn) in Patient 4. Seven previously reported mutations
were also identified: p.Ala510Val (six patients), p.Lys558* (two
patients), p.(Leu78*) (one patient), p.Arg398* (two patients),
p.(Ile743Thr) (one patient), p.(Gly352Argfs*44) (two patients)
and p.(Arg485_Glu487del) (one patient). A single heterozygous
SPG7 mutation was identified in six additional patients, comprising
two further novel mutations: c.184-3C4T (g.19571C4T, pre-
dicted to remove a splice site before exon 2), and c.1067C4T;
p.(Thr356Met); and two previously reported pathogenic muta-
tions: p.Ala510Val (three patients), and p.(Leu78*) (one patient)
(Table 1). The most common mutation was p.Ala510Val, identified
in nine patients (eight probands) from our panel of 68 probands
(12%). No additional mutations or gene rearrangements were
detected after multiplex ligation-dependent probe amplification
analysis. No mutations in AFG3L2 were identified.
Clinical features of patients with SPG7
mutations
Compound heterozygous SPG7 mutations
The clinical features of nine patients with compound heterozygous
SPG7 mutations are summarized in Table 1, Patients 1–9. Mean age
at onset was 40 years (range 28–65 years) with current age 61
years (range 51–71 years). The most frequent clinical features of
our patients were spastic ataxia (all nine patients) with both PEO
and ptosis in eight patients (Fig. 1). Additional features included a
proximal muscle weakness (five patients) and swallowing difficulties
(four patients) resulting in mild to moderate disability. Other symp-
toms typically associated with hereditary spastic paraparesis were less
frequent, including bladder dysfunction (three patients), and optic
atrophy (two patients) resulting in significant visual impairment (one
patient). Dysarthria was common (four patients). Other central
neurological features of mitochondrial disease were not seen, such
as encephalopathy, epilepsy, or stroke-like events, and cognitive im-
pairment was observed in only a single patient (Patient 3 had a
Montreal Cognitive Assessment Tool score of 22/30, losing 5
points for recall and 3 points for visuospatial). Sensorineural hearing
loss was not a feature. Cardiac involvement was not evident.
Cerebellar atrophy was present in all those who underwent magnetic
resonance brain imaging (five patients); this was marked in four pa-
tients and mild in one patient. Motor evoked potentials performed in
two patients with compound heterozygous mutations showed elec-
trophysiological evidence of a length dependent degenerative pro-
cess affecting corticospinal tracts axons projecting to the lower limb
motor neurons (Fig. 2), as classically described in hereditary spastic
paraplegia (Lang et al., 2011).
Single heterozygous mutations
The clinical features of six patients with single heterozygous SPG7
mutations are summarized in Table 1, Patients 10–15. Mean age
at onset was 26 years (range 6–65 years) with current age
66 years (range 44–90 years). PEO (four patients) was the most
common clinical feature in this group of patients and was the only
finding in two patients (Patients 11 and 15). Ataxia (three pa-
tients) and other cerebellar features including nystagmus (one pa-
tient), dysdiadochokinesia (one patient) and cerebellar atrophy
(one patient) were evident. Lower limb spasticity was present in
three patients.
Muscle fatigue was the presenting feature in all of the patients,
followed by a progressive gait ataxia with spasticity. Proximal
weakness developed later in the disease course in some subjects,
and PEO/ptosis was a late feature.
Muscle mitochondrial DNA analysis
Diagnostic histology and oxidative enzyme histochemistry of the
patients’ skeletal muscle biopsies revealed evidence of mitochon-
drial respiratory chain deficiency, with sequential COX-SDH histo-
chemistry confirming variation in the severity of the COX-mosaic
defect (Table 1). These findings were particularly pronounced in
Patient 1 in whom 30% COX-deficient fibres were noted, to-
gether with typical ‘ragged-blue’ fibres indicating subsarcolemmal
mitochondrial accumulation (Fig. 3A). Long-range PCR amplifica-
tion of muscle DNA clearly showed the presence of multiple mito-
chondrial DNA deletions (Fig. 3B), indicative of a disorder of
mitochondrial DNA maintenance. Real-time PCR analysis of indi-
vidual, laser-captured COX-deficient fibres showed that the
majority, but not all, of these fibres harboured high levels of clon-
ally-expanded mitochondrial DNA deletion involving the MTND4
gene (Fig. 3C), a consistent observation in patients with genetic-
ally-proven multiple mitochondrial DNA deletion disorders
(Longley et al., 2006; Hudson et al., 2008; Blakely et al., 2012;
Pitceathly et al., 2012). Similar findings were also noted in Patients
2, 4, 6 and 7 (not shown). No major abnormality of mitochondrial
DNA copy number was detected in muscle DNA from any of the
patients with compound heterozygous SPG7 mutations (Table 1).
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Transcript analysis
Sequencing of complementary DNA derived from fibroblasts in
Patients 2 and 3 only revealed one mutated allele, consistent
with the prediction that these two patients harboured one allele
likely to cause nonsense mediated decay, and confirming that the
heterozygous mutations were in trans (Fig. 4). In accordance with
this, the transcript levels increased following emetine treatment in
two of the patients with nonsense SPG7 mutations (Fig. 5), but
not in the one cell line with two missense SPG7 mutations
(Patient 4). These findings were confirmed by Sanger sequencing
of complementary DNA with transcript-specific primers (Fig. 4).
Reverse-transcriptase quantitative PCR of complementary DNA
derived from muscle demonstrated elevated expression of SPG7,
AFG3L2 and OPA1 transcripts in patients compared with controls
(Fig. 5). The transcript levels of POLG and SDHA did not differ
significantly between patients and controls.
Western blot analysis
Western blot of skeletal muscle protein showed a generalized in-
crease in mitochondrial protein levels in the SPG7 Patients 1, 2, 4,
5 and 7, including markers of mitochondrial mass (SDHA, porin,
and HSP60) and SPG7. By contrast, AFG3L2 protein levels were
reduced in patients compared to controls (Fig. 6).
Mitochondrial network analysis
Fibroblasts from SPG7 patients had fewer mitochondrial networks
(41.42–53.90 compared with 88.66 for controls; Fig. 7), which
were larger than controls. The average network length was
Figure 1 Clinical features. (A) Typical ophthalmological features of a patient with hereditary spastic paraplegia type 7 with PEO: marked
ptosis is evident in primary gaze (i); extraocular motility in cardinal directions of gaze is mildly reduced, with restriction of upgaze most
affected as the patient is asked to look down (ii); up (iii); left (iv); and right (v). (B) T2-weighted MRI images in demonstrating diffuse
cerebellar volume loss, in sagittal (i); and transverse-axial (ii) planes.
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significantly longer for SPG7 patients (4.05–4.78 mm compared
with 3.39mm for control subjects; Fig. 7C) the average length of
the longest network per cell was also significantly higher in SPG7
patients (25.73–42.27 mm compared with 19.92 mm for control
subjects; Fig. 7D), and SPG7 patients had a greater proportion
of long networks (410 mm, 4.4% for the controls compared
with 6.8 to 10.2% for the SPG7 patients; Fig. 7A) when compared
with control subjects. In addition, the average volume per mito-
chondrial network was greater in SPG7 patients, as was the aver-
age total volume of mitochondrial networks per cell (Fig. 7E and
F). All of these findings were highly statistically significant
(P5 0.0001) except for average maximum network length in
Patient 4 (P = 0.004), and no significant difference for total mito-
chondrial network volume per cell in Patient 4. Representative
images from control and SPG7 cell lines are presented in Fig. 8.
Deep resequencing of mitochondrial
DNA
Analysis of FLX ultra-deep resequencing was performed on 375
positions that met our minimum criteria of 410 000-fold cover-
age, with 258 not associated with poly-mononucleotide repeats.
Overall, the frequency of low-level mitochondrial DNA hetero-
plasmy (51%) in SPG7 patients mutations was similar to control
subjects, aged controls, patients with OPA1 mutation and lower
than POLG patients (Fig. 9). However, the number of high-level
heteroplasmies (41%) appeared to be greater in the SPG7 pa-
tients compared with controls or OPA1 patients, in keeping with
an increased rate of clonal expansion of mitochondrial DNA point
mutations, although this difference was not statistically significant
(P = 0.07).
Discussion
Using an unbiased exome sequencing approach we identified
pathogenic compound heterozygous SPG7 mutations in patients
Figure 3 Characterization of mitochondrial DNA maintenance defect in Patient 1. (A) Sequential COX-SDH histochemistry demonstrates
a mosaic distribution of COX-deficient muscle fibres (blue) amongst fibres exhibiting normal COX activity (brown), with significant
evidence of mitochondrial proliferation as shown by enhanced SDH reactivity around the subsarcolemmal region of the muscle fibre
(ragged-blue fibres). (B) Long range PCR amplification of muscle DNA across the major arc shows significant evidence of multiple
mitochondrial DNA deletions. C = Control; P = patient. (C) Quantitative, single fibre real-time-PCR reveals the majority—but not all—of
COX-deficient fibres contain high levels of a clonally-expanded mitochondrial DNA deletion involving the MTND4 gene, an observation
which is consistent with multiple mitochondrial DNA deletions due to a disturbance of mitochondrial DNA maintenance (He et al., 2002).
Figure 2 Motor evoked potentials in Patients 1 and 4. Average
(n = 10) rectified motor cortical evoked potentials (MEPs) re-
corded from (A) hand muscle, the right first dorsal interosseous
(R FDI) and (B) foot muscle right extensor digitorum brevis (R
EDB) in an age-matched male control (aged 64) shown in grey,
Patient 1 (aged 65) in green and Patient 4 (aged 66) in red.
Traces have been aligned after subtracting peripheral motor
conduction times. Dashed lines indicate the onset of each MEP.
Average central motor conduction times (mean  1 SD) for (C)
right first dorsal interosseous and (D) right extensor digitorum
brevis in the same patients. Average central motor conduction
times (CMCTs) were calculated by subtracting the average
peripheral motor conduction time (n = 10) from the average
motor cortical evoked potential latency (n = 10), measured from
unrectified EMG. The solid horizontal lines show the mean,
dashed horizontal lines and grey shaded areas show 2 SD of the
mean from published normal data (Eisen and Shtybel, 1990).
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with PEO and multiple mitochondrial DNA deletions in skeletal
muscle, and confirmed these unexpected findings in a larger
cohort of undiagnosed patients with multiple mitochondrial DNA
deletions. The majority of the compound heterozygotes had at
least one known pathogenic SPG7 mutation, and both transcript
and western blot analyses support a pathogenic role for the other
mutations (Table 1), including novel nonsense mutations causing
nonsense-mediated decay. Although we are unable to provide
proof of pathogenicity for the novel mutations in Patient 4,
these were associated with near-identical clinical findings to the
other SPG7 patients, and had similar abnormalities on western
blot, reverse transcription quantitative PCR, and mitochondrial
network imaging. Given that these mutations affect a critically
important region of the protein (Bonn et al., 2010), they are
highly likely to be pathogenic. The presence of compound hetero-
zygous SPG7 mutations in these nine patients from a cohort of 68
PEO patients indicate that SPG7 mutations are a common cause of
PEO and that this gene should be sequenced in PEO patients with
unexplained multiple deletions of mitochondrial DNA.
Clinical features in patients with
compound heterozygote SPG7
mutations
Given our ascertainment methods, it is not surprising that the
majority of the patients with SPG7 mutations had PEO, usually
associated with marked ptosis. Although this has been previously
reported in association with SPG7 (van Gassen et al., 2012), it was
so uncommon that it was considered possibly a coincidental find-
ing not related to the disorder. Our findings show that PEO and
ptosis fall within the spectrum of complex SPG7 phenotypes, and
Figure 4 Confirmatory complementary DNA sequencing in Patients 2 and 3. Arrows indicate the positions of the mutations. (A) In Patient
2, the c.1192C4T (p.Arg398*) mutation is predicted to cause nonsense mediated messenger RNA decay. At left the genomic sequence
demonstrates this mutation to be present in the heterozygous state although in complementary DNA from fibroblasts it appears absent
because it is degraded by nonsense mediated decay. The presence of this variant is partially restored in fibroblasts grown with emetine (an
inhibitor of nonsense mediated decay). The second mutation in this patient [c.1529C4T; p.(Ala510Val)] is present at homozygous levels
in complementary DNA indicating that it is on the opposite allele; as before the second allele is partially restored with emetine treatment.
(B) Patient 3 has a c.1672A4T (p.Lys558*) mutation which similarly is predicted to cause nonsense mediated decay. The mutation is
almost absent in complementary DNA but partially restored in cells grown with emetine. The second c.1529C4T; p.(Ala510Val) mutation
is again shown to be present on the opposite allele.
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the presence of multiple mitochondrial DNA deletions provides the
likely mechanism. Bladder dysfunction was seen in three patients,
which has been reported in 50% of patients with SPG7-related
hereditary spastic paraplegia (van Gassen et al., 2012). Optic
atrophy, recognized as part of a more severe SPG7 complex pheno-
type (van Gassen et al., 2012), was seen in two patients in our cohort
resulting in significant visual impairment. Although cerebellar ataxia
was a feature of all of the patients with compound heterozygous
SPG7 mutations, cortical manifestations associated with other
forms of mitochondrial disease such as cognitive impairment, epi-
lepsy, encephalopathy and/or stroke-like events were not observed.
Motor evoked potentials performed in two patients showed electro-
physiological abnormalities classical of hereditary spastic paraplegia,
which has infrequently been reported in patients harbouring OPA1
mutations (Yu-Wai-Man et al., 2010; Baker et al., 2011). This pro-
vides further evidence of corticospinal tract dysfunction and indicates
that spasticity is not as rare in mitochondrial disorders as was previ-
ously thought.
Patients with single heterozygous
SPG7 mutations
Although it is possible that a second recessive SPG7 variant is present
in an area outside our analysis, perhaps in a regulatory region of the
gene, dominant SPG7 mutations have been described (Sanchez-
Ferrero et al., 2013), and diffusion tensor imaging demonstrated
abnormalities in an asymptomatic heterozygote SPG7 mutation car-
rier (Warnecke et al., 2010). Furthermore, even after excluding the
Figure 6 Western blot of muscle tissue. (A–C) Representative
blots used in the quantification of protein expression of muscle
tissue from five patients with compound heterozygous SPG7
mutations and three control subjects. Testing was performed in
triplicate and quantification of aggregate mean with SD
(normalized to GAPDH) are represented in D. Markers of
mitochondrial mass, including SDHA, porin, and HSP60 are
significantly increased in SPG7 patients compared with controls.
SPG7 and OPA1 were also significantly elevated in SPG7
patients compared with controls. AGF3L2 was decreased
compared with controls. All the above were statistically
significant to *P50.01.
Figure 5 Transcript level measurement with reverse transcrip-
tion quantitative PCR. (A) SPG7 transcript analysis in Patients
1–4, using RNA from cultured fibroblasts. For Patients 1–3 who
have one or more nonsense mutations in SPG7, treatment of
fibroblasts with emetine (dark bars) (an inhibitor of nonsense-
mediated messenger RNA decay) compared with normal
conditions (light bars), resulted in significantly increased SPG7
messenger RNA in Patients 1 and 2 (*P50.05). Patient 4 who
has 2 missense SPG7 mutations does not have alteration in SPG7
expression with emetine (nor do control; data not shown).
(B) Transcript quantitation in complementary DNA derived from
muscle, in Patients 1–4 (red bands), compared with three control
muscle samples (blue bands). Levels of SPG7, AFG3L2, and
OPA1 transcripts are elevated in patients compared with
controls (*P50.02). Levels of POLG and SDHA did not
differ significantly.
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compound heterozygotes from our study, SPG7 mutations remain
significantly enriched in the remaining 60 patients: the common
p.Ala510Val mutation is present in 3 of 118 chromosomes (2.5%)
but among regionally-matched controls only 1 in 192 chromosomes
(0.5%). Given that the majority of the patients with single hetero-
zygous mutations in SPG7 had a similar phenotype to the patients
with compound heterozygous mutations, the heterozygous muta-
tions are likely to be involved in the pathogenesis of the disorder
in these patients. Although only one of six heterozygotes we studied
reported a relevant family history, incomplete penetrance for
presumed dominant SPG7 mutations has been reported previously
(Sanchez Ferrero et al., 2013). Further familial segregation studies
are warranted to definitely determine the inheritance pattern for the
presumed dominant SPG7 mutations described here.
Novel mutations in SPG7
We demonstrate evidence of pathogenicity for three mutations
(p.Asn288*, p.Arg398* and p.Lys558*) that are predicted to
cause nonsense-mediated messenger RNA decay. One of these,
Figure 7 Mitochondrial network analysis. Mitochondrial network analysis was undertaken in fibroblasts (Patients 1–4) grown concur-
rently with identical medium and conditions. Error bars are SD. Controls are the aggregate results of four separate cell lines (50 cells each
for total 200 cells). (A) The distribution of the network lengths is demonstrated; very long networks (410 mm) were significantly more
abundant in patients with compound heterozygous SPG7 mutations than controls. (B) The average number of total networks per cell was
significantly lower in SPG7 patients. (C) The average length per mitochondrial network was increased in SPG7 patients, as was the average
longest network per cell (D). The volume of individual mitochondrial networks was higher than controls per cell line (E) and the total
volume of the mitochondrial network per cell was elevated (in all cell lines except Patient 4 which was not significant) (F). We suggest that
these hyperfused mitochondrial networks may be a compensatory mechanism, and that the elevated total mitochondrial volume
corresponds to the elevated mitochondrial mass observed in COX-deficient fibres in these patients. *P50.0001 and **P = 0.004.
1332 | Brain 2014: 137; 1323–1336 G. Pfeffer et al.
p.Asn288*, is a novel mutation, whereas the others have been
previously reported in hereditary spastic paraplegia type 7 patients
(Schlipf et al., 2011; van Gassen et al., 2012). Our studies in
fibroblasts derived from these patients demonstrate that emetine
treatment increases the transcript levels. This was directly shown
using reverse transcriptase quantitative PCR in Patients 1 and 2,
who had increased SPG7 transcript levels (Fig. 5A), and indirectly
in Patients 2 and 3 in whom the degraded transcript was detect-
able with Sanger sequencing upon treatment with emetine
(Fig. 4). The consistency of our findings on western blot, reverse
transcriptase quantitative PCR, and mitochondrial network ima-
ging among Patients 1–4 (and as distinguished from control sub-
jects) is indirectly suggestive that the two novel mutations in
Patient 4 [p.(Glu741Lys) and p.(Asp742Asn)] are pathogenic.
Functional consequences of the SPG7
mutations
Several strands of evidence indicate that SPG7 mutations induce
mitochondrial biogenesis. Histochemically we observed ragged-red
fibres in skeletal muscle (Fig. 3), supported by a generalized upre-
gulation of mitochondrial proteins on western blot analysis (SDHA,
porin and HSP60); and mitochondrial network analysis revealed an
increased cellular mitochondrial mass in fibroblasts. Reverse tran-
scriptase quantitative PCR of transcript levels from muscle RNA did
not demonstrate elevated SDHA although other mitochondrial
proteins had increased transcript levels (SPG7, AFG3L2 and
OPA1). Taken together, these findings all support upregulation
of mitochondrial gene expression, protein synthesis and increased
mitochondrial mass, which are typical for a mitochondrial disorder,
where the organellar proliferation is thought to be a compensatory
response to malfunctioning mitochondria. This increased mito-
chondrial biogenesis may attenuate end-organ dysfunction and
explain the late onset of disease in most of our patients. The
upregulation of mitochondrial proteins may also indicate an un-
folded protein response caused by decreased paraplegin activity,
which was demonstrated to occur in a SPG7 RNA knockdown
study in a Caenorhabditis elegans model (Yoneda et al., 2004).
It is intriguing that these findings are the mirror image of those
seen in mice with mutations in Afg3l2, the binding partner of
Figure 8 Representative images from mitochondrial network analysis. Three-dimensional reconstruction of mitochondrial networks using
Huygens Essentials software. Networks are colour-coded, in which short networks are yellow and longer networks are red. (A and B)
Representative images of the networks from two separate control cell lines. (C and D) Representative images from cell lines derived from
Patients 1 and 4, respectively. Qualitatively, one can observe that networks appear to be longer in the patient with compound hetero-
zygous SPG7 mutations. Statistical analysis indicated that SPG7 patient cell networks were on average longer, with fewer networks but
increased total volume of mitochondria.
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paraplegin, which exhibit decreased mitochondrial protein synthe-
sis and fragmented mitochondrial networks, leading to neurode-
generation (Almajan et al., 2012). This is thought to be due to the
impaired metabolism of OPA1, which mediates mitochondrial
fusion (Maltecca et al., 2012). In contrast, in our patients with
SPG7 mutations we observed increased mitochondrial biogenesis
with hyper-fused mitochondria. This again is likely to be part of a
compensatory response, known as stress-induced mitochondrial
hyperfusion (Tondera et al., 2009). The generalized upregulation
of OPA1 that we observed in skeletal muscle is likely to play a role
in this response, as Opa1 isoforms are a key mediator of mito-
chondrial hyperfusion (Song et al., 2007). It is unclear whether the
paraplegin defects in these patients would have directly caused the
elevated OPA1 levels, as previous work in animal models indicated
that abnormal paraplegin is not sufficient to alter OPA1 metabol-
ism (Duvezin-Caubet et al., 2007; Ehses et al., 2009).
How are these abnormalities linked to the secondary mutations
of mitochondrial DNA present in our patients? There was no sig-
nificant increase in the point mutation burden on deep sequencing
of muscle mitochondrial DNA from SPG7 patients, with similar
levels to age-matched controls and OPA1 patients, but signifi-
cantly lower than in POLG patients (who are known to have a
proofread-deficient mitochondrial DNA polymerase). The major
mechanism leading to the increase in detectable mutations is
therefore likely to be the segregation and clonal expansion of
pre-existing deletions and point mutations, rather than an increase
in the mutation rate per se, given that low-level mitochondrial
DNA heteroplasmy seems to be a common finding in healthy in-
dividuals (Payne et al., 2013). Initially this could be driven by
mitochondrial biogenesis triggered by a disruption of mitochon-
drial quality control, in which paraplegin is intimately involved.
The mitochondrial DNA replication which accompanied the bio-
genesis would lead to the accumulation of pre-existing mitochon-
drial DNA mutations. Once these mutations reach a critical level,
they would lead to further biogenesis and the formation of
ragged-red fibres. The combined effect would be a vicious cycle
of events, leading to the accumulation of more mitochondrial DNA
mutations, a COX-defect, and the subsequent PEO-phenotype.
The clonal expansion of somatic mitochondrial DNA mutations
provides a common mechanism for the PEO, ptosis and myopathy
seen in several mitochondrial DNA maintenance disorders, and our
data suggest that the same is occurring in SPG7. However, it re-
mains to be elucidated as to whether this same mechanism con-
tributes to the motor system degeneration where a different
mechanism may be operating. This also appears to be the case
for OPA1, where the optic nerve degeneration does not appear to
be mediated through clonally expanded mitochondrial DNA mu-
tations (Yu-Wai-Man et al., 2009). When taken together, these
findings highlight the multiple downstream mechanisms that con-
tribute to the clinical phenotype of ostensibly simple single-gene
(monogenic) disorders. Why this should only occur in some mu-
tation carriers remains to be determined, and it may depend upon
the region of SPG7 that is involved.
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Figure 9 Ultra-deep resequencing of mitochondrial DNA
control region. Ultra-deep resequencing by synthesis (UDS) of
skeletal muscle mitochondrial DNA. UDS (Roche 454 FLX
Titanium) mitochondrial DNA hypervariable segment 2 (MT-
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